Evidence map›Paper›PMID 40473896›Full record

ArticleCommunications biology2025

Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines.

Ian Y Luk, Jennifer K Mooi, Dmitri Mouradov, Tao Tan, Cameron M Scott, Fiona Chionh, Laura J Jenkins, Camilla M Reehorst, Rebecca Nightingale, Peter Savas and 16 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ian Y Luk *Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Jennifer K Mooi *Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Dmitri Mouradov *Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
Tao TanWalter and Eliza Hall Institute, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5924-4112
Cameron M ScottOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Fiona ChionhOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Laura J JenkinsOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Camilla M ReehorstOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8039-3582
Rebecca NightingaleOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Peter SavasPeter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5999-428X
Janson Wt TseOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Rebekah Li CrakeOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Eduard BatlleInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0003-2422-0326
Diego ArangoBiomedical Research Institute of Lleida, IRBLleida, Lleida, Spain.ORCID http://orcid.org/0000-0003-2953-3284
Higino DopesoMemorial Sloan-Kettering, New York, NY, USA.ORCID http://orcid.org/0000-0003-0060-1861
Peter GibbsWalter and Eliza Hall Institute, Melbourne, Victoria, Australia.
Niall C TebbuttOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Rod B LuworDepartment of Surgery, University of Melbourne, Parkville, Victoria, Australia.
Andrew M ScottOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Faiza BasheerInstitute of Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Amardeep S DhillonInstitute of Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Nicholas J ClemonsPeter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-9283-9978
David S WilliamsOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Ron FiresteinCentre for Cancer Research, Hudson Institute for Medical Research, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5255-1838
Oliver M SieberWalter and Eliza Hall Institute, Melbourne, Victoria, Australia. sieber.o@wehi.edu.au.ORCID http://orcid.org/0000-0001-9480-0786
John M MariadasonOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia. john.mariadason@onjcri.org.au.ORCID http://orcid.org/0000-0001-9123-7684

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Department of Health | National Health and Medical Research Council (NHMRC) 1046092NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Colorectal cancers (CRCs) present across a range of differentiation grades, which impact patient outcome and management; however, the molecular features and drivers of differentiation status are not fully understood. To address this, 84 commonly used human CRC cell lines were grown as xenografts in mice, revealing models of low-grade (LG) and high-grade (HG) CRC. Transcriptional profiling revealed coordinate downregulation of multiple transcription factors involved in intestinal development and differentiation, markers of colonic lineage-specific differentiation, and effectors of normal functions of the colonic epithelium in HG tumours. Mechanistically, multiple genes suppressed in HG tumours harboured promoter methylation, indicative of stable epigenetic silencing. Furthermore, markers of LGR5+ colon stem cells were suppressed in HG tumours, while markers of cell proliferation, fetal-like intestinal stem cells, and non-canonical cell types including mesenchymal cells were increased. These changes manifested in HG cell line displaying increased proliferation, migration and metastatic capacity. Importantly, CRC cell line-derived transcriptional profiles of differentiation grade were reflected in LG and HG patient-derived tumour organoids and primary CRCs, revealing cell lines accurately model differentiation grade. The models and tumour differentiation-related properties identified herein may inform new approaches for tailored CRC treatments based on tumour grade.

Indexed as

Colorectal NeoplasmsAnimalsCell DifferentiationCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceNeoplasm Grading

Identifiers

PMID40473896
PMCPMC12141688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.